financetom
Business
financetom
/
Business
/
Honeywell Board Approves Spin-off of Solstice Advanced Materials
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Honeywell Board Approves Spin-off of Solstice Advanced Materials
Oct 16, 2025 4:58 AM

07:31 AM EDT, 10/16/2025 (MT Newswires) -- Honeywell International ( HON ) said Thursday its board has approved the planned spin-off of Solstice Advanced Materials.

The company said on Oct. 30 it will distribute all shares of Solstice pro rata to shareowners of record on Oct. 17, on the basis of one share of Solstice for every four Honeywell ( HON ) shares.

Solstice will be a pure-play specialty materials company with market positions in refrigerants, semiconductor materials, data center cooling, alternative energy, protective fibers and healthcare packaging, the company said.

Solstice shares are expected to begin trading on Nasdaq on a "when-issued" basis on Oct. 20, under the ticker symbol "SOLSV." Regular trading is expected to begin on Oct. 30 under the ticker symbol "SOLS," the company said.

Honeywell ( HON ) shares were 0.7% higher in premarket trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly's Eloralintide Shows Up to 20.1% Weight Loss in Phase 2 Trial Patients
Eli Lilly's Eloralintide Shows Up to 20.1% Weight Loss in Phase 2 Trial Patients
Nov 6, 2025
08:50 AM EST, 11/06/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday its eloralintide, an investigational once-weekly, selective amylin receptor agonist, demonstrated superior mean weight reductions from 9.5% to 20.1% in a phase 2 trial. The trial featured 263 adults with obesity or who are overweight with at least one obesity-related comorbidity and without type 2 diabetes, the...
Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle
Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle
Nov 6, 2025
NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera ( MTSR ) was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer ( PFE ) to win Metsera's ( MTSR ) obesity drug assets. Reuters reported that Pfizer ( PFE ) was planning to sweeten its bid...
BRIEF-Bombardier CEO says leaving door open to incremental M&A for services, defense business - conf. call
BRIEF-Bombardier CEO says leaving door open to incremental M&A for services, defense business - conf. call
Nov 6, 2025
Nov 6 (Reuters) - Bombardier Inc ( BDRPF ): * BOMBARDIER CEO SAYS LEAVING THE DOOR OPEN TO INCREMENTAL M&A FOR SERVICES AND DEFENSE BUSINESS - CONF. CALL * BOMBARDIER CFO SAYS SUPPLY CHAIN HAS NORMALIZED WITH EXCEPTION OF ENGINES * BOMBARDIER CEO SAYS CO ASSESSING WHETHER TO RAISE JET PRODUCTION Further company coverage: ...
Medical Facilities Reports Lower Q3 Income
Medical Facilities Reports Lower Q3 Income
Nov 6, 2025
08:49 AM EST, 11/06/2025 (MT Newswires) -- Medical Facilities ( MFCSF ) reported Thursday a 7.6% year-on-year decline in net income for the third quarter. The company booked net income from continuing operations of US$12.9 million, or $0.23 per diluted share, down from $14.0 million, or $0.23 per diluted share. Revenue and other income slipped 7% to $82.6 million while...
Copyright 2023-2026 - www.financetom.com All Rights Reserved